Arvinas Inc (NASDAQ:ARVN) Major Shareholder Ventures Iii L.P. 5Am Sells 361,129 Shares

Arvinas Inc (NASDAQ:ARVN) major shareholder Ventures Iii L.P. 5Am sold 361,129 shares of the business’s stock in a transaction on Thursday, March 28th. The stock was sold at an average price of $14.16, for a total transaction of $5,113,586.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Shares of Arvinas stock traded up $0.07 during trading on Wednesday, reaching $22.70. The company had a trading volume of 102,000 shares, compared to its average volume of 115,484. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.52 and a current ratio of 8.52. Arvinas Inc has a fifty-two week low of $10.19 and a fifty-two week high of $25.61. The firm has a market cap of $738.33 million and a PE ratio of -0.89.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings data on Tuesday, March 26th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.08. The business had revenue of $3.44 million for the quarter, compared to the consensus estimate of $3.38 million. On average, equities analysts predict that Arvinas Inc will post -2.09 earnings per share for the current year.

Several large investors have recently made changes to their positions in the stock. Strs Ohio bought a new stake in shares of Arvinas during the 4th quarter valued at about $26,000. American International Group Inc. bought a new stake in shares of Arvinas during the 4th quarter valued at about $66,000. Deutsche Bank AG bought a new position in Arvinas in the 4th quarter worth about $135,000. Diag Capital Management LP bought a new position in Arvinas in the 4th quarter worth about $311,000. Finally, Citadel Advisors LLC bought a new position in Arvinas in the 3rd quarter worth about $463,000. 41.05% of the stock is owned by institutional investors and hedge funds.

A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Arvinas from a “hold” rating to a “sell” rating in a research note on Friday, April 19th. Evercore ISI assumed coverage on shares of Arvinas in a research note on Thursday, April 11th. They issued an “outperform” rating on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. Arvinas presently has an average rating of “Hold” and a consensus price target of $20.33.

WARNING: “Arvinas Inc (NASDAQ:ARVN) Major Shareholder Ventures Iii L.P. 5Am Sells 361,129 Shares” was posted by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/04/24/arvinas-inc-arvn-major-shareholder-ventures-iii-l-p-5am-sells-361129-shares.html.

Arvinas Company Profile

Arvinas Holding Company, LLC, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER+ breast cancer.

See Also: Ex-Dividend

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.